--- title: "Pre-market hot trades in US stocks: Wingstop pre-market down 8.65%; Werewolf Therapeutics pre-market up 7.97%" type: "News" locale: "en" url: "https://longbridge.com/en/news/284565170.md" description: "Wingstop pre-market down 8.65%; Werewolf Therapeutics pre-market up 7.97%; Inno pre-market up 74.25%; Sagtec Global pre-market up 45.31%; KalVista Pharmaceuticals pre-market up 38.62%" datetime: "2026-04-29T11:57:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284565170.md) - [en](https://longbridge.com/en/news/284565170.md) - [zh-HK](https://longbridge.com/zh-HK/news/284565170.md) --- # Pre-market hot trades in US stocks: Wingstop pre-market down 8.65%; Werewolf Therapeutics pre-market up 7.97% **Pre-market Hot Trades in US Stocks** Wingstop is down 8.65% in pre-market trading. Based on recent key news: 1. On April 29, Wingstop announced its first-quarter financial report, showing a same-store sales growth decline of 2.2%, with net income of $29.883 million, below market expectations, leading to a drop in stock price. Source: Reuters 2. On April 27, a UBS analyst report pointed out that the US restaurant industry showed a slowdown at the end of the first quarter, with an unclear consumer environment, and Wingstop may lower its comparable sales outlook, increasing market concerns. Source: AASTOCKS 3. On April 29, Wingstop updated its guidance for 2026, expecting a slight decline in domestic same-store sales, with high uncertainty in the macro environment affecting investor confidence. Source: Reuters The overall performance of the restaurant industry is stable, but uncertainty is high. Werewolf Therapeutics is up 7.97% in pre-market trading, with no significant news recently. The trading is active, with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. **Top Gainers in Pre-market US Stocks** Inno is up 74.25% in pre-market trading, with no significant news recently. The trading is active, with clear capital flow, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Sagtec Global is up 45.31% in pre-market trading. Based on recent key news: 1. On April 29, Sagtec Global announced record revenue of $19.1 million for the fiscal year 2025, a year-on-year increase of 49%. This strong performance significantly boosted market confidence, driving the stock price up sharply. 2. On April 29, Sagtec Global issued a forward-looking statement detailing the company's growth prospects in AI platform adoption, new market expansion, and future monetization strategies. Despite the risks and uncertainties associated with these statements, the market's optimistic expectations for the company's future development further propelled the stock price increase. 3. On April 28, Sagtec Global corrected the dates for its financial report release and conference call, ensuring that investors and stakeholders correctly marked their calendars. This move helps maintain the company's transparency and investor confidence, indirectly supporting the stock price increase. The technology sector is performing strongly overall, with significant capital inflow. KalVista Pharmaceuticals is up 38.62% in pre-market trading. Based on recent key news: 1. On April 29, Italian pharmaceutical company Chiesi announced its acquisition of KalVista Pharmaceuticals for approximately $1.9 billion. This transaction will expand Chiesi's rare immunology product portfolio, significantly boosting KalVista's stock price. Source: Financial Associated Press 2. On April 29, Chiesi plans to achieve its 2030 revenue target through the acquisition of KalVista's EKTERLY (sebetralstat) drug This move has strengthened the market's confidence in KalVista's future growth. Source: Reuters On April 29, Chiesi's Chief Financial Officer stated that this acquisition will accelerate the company's influence in the rare disease sector, further enhancing investor interest in KalVista. Source: Reuters The rare disease drug market has significant growth potential ### Related Stocks - [WING.US](https://longbridge.com/en/quote/WING.US.md) - [HOWL.US](https://longbridge.com/en/quote/HOWL.US.md) - [INHD.US](https://longbridge.com/en/quote/INHD.US.md) - [SAGT.US](https://longbridge.com/en/quote/SAGT.US.md) - [KALV.US](https://longbridge.com/en/quote/KALV.US.md) ## Related News & Research - [Wingstop Debuts 'House of Flavor' Fan Experience in North America for the First Time | WING Stock News](https://longbridge.com/en/news/286408258.md) - [Wingstop Tumbles As Chicken Demand Falters, Guidance Cut](https://longbridge.com/en/news/284579689.md) - [Wingstop Posts Record 2025 Growth Despite Sales Decline](https://longbridge.com/en/news/276232591.md) - [Wingstop rallies after same-store sales don't fall as much as anticipated](https://longbridge.com/en/news/276234306.md) - [BTIG Keeps Their Buy Rating on Wingstop (WING)](https://longbridge.com/en/news/284761649.md)